Related Experiment Videos
Urinary NMP22 and renal cell carcinoma
1Department of Urology, Kaiser Permanente Southern California, Los Angeles, California 90027, USA.
Urology
|February 25, 2000
Summary
Elevated nuclear matrix protein 22 (NMP22) in urine may indicate kidney cancer (RCC). This biomarker, typically used for bladder cancer detection, shows higher levels in patients with renal cell carcinoma, suggesting broader diagnostic potential.
Area of Science:
- Urology
- Oncology
- Biomarker Research
Background:
- Urinary nuclear matrix protein 22 (NMP22) is established for detecting recurrent bladder cancer.
- The potential utility of NMP22 in diagnosing other renal pathologies is not widely explored.
Purpose of the Study:
- To investigate the incidence of elevated urinary NMP22 levels in patients diagnosed with renal cell carcinoma (RCC).
- To assess if NMP22 can serve as a potential biomarker for kidney cancer detection.
Main Methods:
- Urinary NMP22 levels were measured in 65 patients undergoing abdominal imaging.
- A cohort of 32 patients with solid renal masses (30 confirmed as RCC) and 33 controls were analyzed.
- Patients with RCC underwent nephrectomy, with pathological confirmation.
Main Results:
- Urinary NMP22 values were significantly higher in patients with RCC compared to the control group (13.69 U/mL vs. 3.03 U/mL, P <0.0078).
- 40% of RCC patients (12 out of 30) exhibited positive NMP22 levels (≥10 U/mL).
- Two false-positive results were observed in the control group.
Conclusions:
- Elevated urinary NMP22 levels are associated with renal cell carcinoma, suggesting its potential beyond bladder cancer detection.
- This finding may lead to increased incidental detection of kidney cancer.
- Further research into more specific NMP assays could enhance RCC diagnosis.